Low expression of PRMT5 in peripheral blood may serve as a potential independent risk factor in assessments of the risk of stable CAD and AMI
Low expression of PRMT5 in peripheral blood may serve as a potential independent risk factor in assessments of the risk of stable CAD and AMI
复制标题
DOI：
10.1186/s12872-019-1008-4
复制
发表时间：
2019-01-31
影响因子：
2.1
通讯作者：
Meng, Fanbo
中科院分区：
文献类型：
--
作者：
Tan, Buchuan;Liu, Qian;Meng, Fanbo
蛋白精氨酸甲基转移酶（PRMTs）可以催化精氨酸的甲基化，并参与许多重要的细胞反应过程。本研究的目的是确定外周血PRMT5基因的表达水平是否可以作为预测急性心肌梗死（AMI）风险的生物标志物。方法采集91例AMI患者和87例稳定期冠心病（CAD）患者外周血。采用实时荧光定量PCR检测PRMT5基因在mRNA水平的表达水平，采用western blot分析检测PRMT5基因在蛋白水平的表达水平。结果在RNA和蛋白水平上，AMI患者外周血PRMT5基因的表达水平均显著低于稳定型CAD患者外周血PRMT5基因的表达水平（Z=-4.813， P=0.000）。PRMT5基因的低表达与冠状动脉Gensini评分相关（rs=-0.205， P=0.015），但与血脂水平、心肌肌钙蛋白水平（rs=-0.125， P=0.413）及发病时间间隔无关（rs=-0.146， P=0.211）。外周血PRMT5低表达的患者发生AMI的可能性是其他患者的5.472倍。结论与稳定型冠心病患者相比，AMI患者外周血PRMT5基因表达较低。外周血PRMT5基因表达低的患者比稳定的冠心病患者更容易发生AMI。PRMT5基因的低表达是AMI发生的独立危险因素。
BackgroundProtein arginine methyltransferases (PRMTs) can catalyse the methylation of arginine and participate in many important cellular reaction processes. The purpose of this research is to determine whether the expression levels of the PRMT5 gene in peripheral blood can be used as a biomarker for predicting the risk of Acute Myocardial Infarction (AMI).MethodsIn this research, peripheral blood was collected from 91 patients with AMI and 87 patients with stable coronary artery disease (CAD). Real-time fluorescent quantitative PCR was performed to measure the expression levels of the PRMT5 gene at the mRNA level, and a western blot analysis was performed to measure the expression levels of the PRMT5 gene at the protein level.ResultsThe results indicate that at both the RNA and protein levels, the expression levels of the PRMT5 gene in peripheral blood from patients with AMI are significantly lower than those in peripheral blood from patients with stable CAD (Z=-4.813, P=0.000). The low expression of the PRMT5 gene is relevant to the Gensini score of the coronary artery (rs=-0.205, P=0.015) but is irrelevant to the serum level of blood lipids, level of cardiac troponin (rs=-0.125, P=0.413) and time intervals of occurrence (rs=-0.146, P=0.211). Patients who have a low PRMT5 expression in the peripheral blood are 5.472 times more likely to suffer from AMI than other patients.ConclusionCompared to stable CAD patients, AMI patients have a lower expression of the PRMT5 gene in their peripheral blood. Patients who have low PRMT5 gene expression in the peripheral blood are more likely to suffer from AMI than those with stable CAD. A low expression of the PRMT5 gene serves as an independent risk factor for the occurrence of AMI.